NEUROCRINE BIOSCIENCES, INC.

Public Equity (NASDAQ)BiotechPublicNeuroscience

📍 San Diego, CA, USA• Founded 1992

StreetZero Signal 54

Be the first to signal interest

About NEUROCRINE BIOSCIENCES, INC.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing treatments for neurological, endocrine and psychiatric disorders. Its commercial product INGREZZA (valbenazine) is approved for tardive dyskinesia and chorea associated with Huntington’s disease. The company is headquartered in San Diego and trades on NASDAQ under the ticker NBIX.

LATEST FUNDINGRule 144

$44K

Announced 2026-10-30

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for NEUROCRINE BIOSCIENCES, INC..

Create free account Sign in

Free plan includes 3 full deal profiles every month.

EMPLOYEES—

FOUNDED1992

HQSan Diego, CA, USA

Industry

Public Equity (NASDAQ)

Investors

Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.

Key highlights

Rule 144 transaction of $43,914 reported with undisclosed investors.
Publicly traded neuroscience company on NASDAQ (NBIX).
Commercial-stage with approved product INGREZZA for movement disorders.
Headquartered in San Diego, California.

Ask StreetZero about NEUROCRINE BIOSCIENCES, INC.

Put our AI to work on this deal.

What is NEUROCRINE BIOSCIENCES, INC.'s value proposition?Who are NEUROCRINE BIOSCIENCES, INC.'s competitors?Why does this raise matter?Summarize NEUROCRINE BIOSCIENCES, INC. for an investor.

Similar companies

Other Public Equity (NASDAQ) deals, ranked by Signal.

Walmart Inc.

$20.5M

Paylocity Holding Corporation

$66.0M

BENTLEY SYSTEMS INC

$67.5M

Crowdstrike Holdings, Inc.

$141.0M

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.